Compare Amgen, Inc. (AMGN) vs Dow Inc (DOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Dow Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Dow Inc trades at $29.31 (market cap $20.92B). The key difference: Amgen, Inc. is far larger — about 9.4× Dow Inc's market cap, and Dow Inc pays the higher dividend (4.82%). Which is the better fit depends on your goals.
| AMGN | DOW | |
|---|---|---|
Market Cap | $196.12B | $20.92B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $41.87 |
52-Week Low | $271.18 | $20.65 |
Enterprise Value | $241.41B | $36.70B |
Dividend Yield | 2.77% | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
DOW trades at $29.03, up 1.86% today, but remains in a bearish technical trend with support near $28. The company reported a net loss of $2.62 billion in 2025, with negative profit margins and declining revenue, though it has beaten EPS estimates in recent quarters. Analyst consensus is a 'Hold' with a $36.11 price target, indicating potential upside if fundamentals improve.
The outlook is cautious; while liquidity supports dividends and the stock trades below book value, persistent losses and high debt pose significant risks. Investor sentiment is mixed amid broader market volatility, with earnings performance being the critical factor for any sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →
